Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

BACKGROUND: Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied in detail whether it could generate specific immunity at mucosal sites, which represent the primary route of entry of SARS-CoV-2. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzi, Lorenzo, Dalla Gasperina, Daniela, Veronesi, Giovanni, Shallak, Mariam, Ietto, Giuseppe, Iovino, Domenico, Baj, Andreina, Gianfagna, Francesco, Maurino, Vittorio, Focosi, Daniele, Maggi, Fabrizio, Ferrario, Marco Mario, Dentali, Francesco, Carcano, Giulio, Tagliabue, Angelo, Maffioli, Lorenzo Stefano, Accolla, Roberto Sergio, Forlani, Greta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718969/
https://www.ncbi.nlm.nih.gov/pubmed/34954658
http://dx.doi.org/10.1016/j.ebiom.2021.103788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718969/
https://www.ncbi.nlm.nih.gov/pubmed/34954658
http://dx.doi.org/10.1016/j.ebiom.2021.103788

Ejemplares similares